Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.
Featured Video
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision
CIDP
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
12:15 MIN
CIDP
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
SHARE
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
Jeffrey A. Allen, MD
University of Minnesota
12:15 MIN
CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
IgG Levels and Wear Off Reflect Administration and Outcome
Carol L. Koski, MD
GBS/CIDP Foundation International
5:51 MIN
CIDP
GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and tr...
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
NOW PLAYING
12:15
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
NOW PLAYING
5:51
IgG Levels and Wear Off Reflect Administration and Outcome
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
NOW PLAYING
14:01
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
Learn how an algorithm could be used to personalize dosing schedules for IVIg.
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
CIDP
GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
CIDP
GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
What is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?